C6orf52

Across TCGA pan-cancer cohorts, C6orf52 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C6orf52 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C6orf52 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C6orf52 expression acts as an unfavorable survival marker.

PDAC and LSCC are the cancer types where C6orf52 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.238	0.569	.044	2	view →
LSCC	DFS	Median	II,III,IV	0.794	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C6orf52–PDAC (DFS)

Open the PDAC breakdown →